Skip to content

Menu

LexBlog, Inc. logo
NetworkSub-MenuBrowse by SubjectBrowse by PublisherJoin the NetworkGet StartedSubscribeSupport
Contact Us
Search
Close

Hollywood puts appearances above all in fad injections of diabetes drug

By Patrick A. Malone on September 28, 2022
Email this postTweet this postLike this postShare this post on LinkedIn

ozempicpen-300x129Troubling but perhaps predictable news is traveling from a vanity trend-setting capital of this country: Hollywood stars have made the taking of a relatively new prescription drug, targeted for the treatment of diabetes, into a fad.

The injectable drug semaglutide, whose brand name is Ozempic, has become a must-have among A-listers because of one of its important outcomes among most users: dramatic weight loss. As Variety, one of the entertainment industry’s leading trade-media sources, reported about Ozempic:

“The drug is an insulin regulator for the pre-diabetic, made by the Danish pharma juggernaut Novo Nordisk, whose primary side effect is dramatic weight loss. It has saturated the industry in recent months, helping the beautiful and wealthy shed extra pounds in the never-ending Los Angeles pastime of optimizing appearances. Hollywood nutritionist Matt Mahowald tells Variety that the chief benefits of the injections are ‘moderating and pulling back insulin secretion and slowing down your stomach from emptying. It promotes satiation from food.’

Continue reading
Photo of Patrick A. Malone Patrick A. Malone
Email
  • Posted in:
    Health Care and Life Sciences
  • Blog:
    DC Medical Malpractice & Patient Safety Blog
  • Organization:
    Patrick Malone & Associates
  • Article: View Original Source

Call us at 1-800-913-0988 or email sales@lexblog.com.

Facebook LinkedIn Twitter RSS
  • About LexBlog
  • The Field We Built
  • Our Beliefs
  • Our Team
  • Contact LexBlog
  • Disclaimer
  • Editorial Policy
  • Terms of Service
  • Get Started
  • Publishing Solutions
  • Compass
  • Submit a Request
  • Support Center
  • System Status
Copyright © 2026, LexBlog, Inc. All Rights Reserved.
Law blog design & platform by LexBlog LexBlog Logo